Selected article for: "SARS cov and target cell"
Author: Shay Leary; Silvana Gaudieri; Abha Chopra; Suman Pakala; Eric Alves; Mina John; Suman Das; Simon Mallal; Phillips Jane Phillips
Title: Three adjacent nucleotide changes spanning two residues in SARS-CoV-2 nucleoprotein: possible homologous recombination from the transcription-regulating sequence
  • Document date: 2020_4_11
    • ID: 9xueqdri_19
    Snippet: Selection of viral adaptations to polymorphic host responses mediated by T cells, NKcells, antibodies and antiviral drugs are well described for other RNA viruses such as HIV and HCV 4, 11 . HIV-1 adaptations to human leucocyte antigen (HLA)-restricted T-cell responses have also been shown to be transmitted and accumulate over time 12, 13 . As previously shown for SARS-CoV, T-cell responses against SARS-CoV-2 are likely to target the nucleocapsid.....
    Document: Selection of viral adaptations to polymorphic host responses mediated by T cells, NKcells, antibodies and antiviral drugs are well described for other RNA viruses such as HIV and HCV 4, 11 . HIV-1 adaptations to human leucocyte antigen (HLA)-restricted T-cell responses have also been shown to be transmitted and accumulate over time 12, 13 . As previously shown for SARS-CoV, T-cell responses against SARS-CoV-2 are likely to target the nucleocapsid 14 . Notably, SARS-CoV-2 R203K/G204R polymorphisms modify the predicted binding of the HLA-C*07 allele to a putative Tcell epitope containing these residues. Escape from HLA-C-restricted T-cell responses may conceivably confer a fitness advantage for SARS-CoV-2, particularly in European populations where HLA-C*07 is prevalent and carried by >40% of the population (www.allelefrequencies.net).

    Search related documents:
    Co phrase search for related documents
    • antiviral drug and predict binding: 1, 2, 3
    • antiviral drug and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
    • antiviral drug and viral adaptation: 1, 2, 3
    • european population and HLA allele: 1
    • european population and host response: 1, 2
    • european population and predict binding: 1
    • fitness advantage and RNA virus: 1, 2, 3
    • fitness advantage and SARS fitness advantage: 1
    • fitness advantage and viral adaptation: 1, 2
    • HLA allele and host response: 1, 2
    • HLA allele and predict binding: 1, 2, 3, 4, 5, 6
    • HLA allele and RNA virus: 1
    • HLA allele predict binding and predict binding: 1